shakedown.social is one of the many independent Mastodon servers you can use to participate in the fediverse.
A community for live music fans with roots in the jam scene. Shakedown Social is run by a team of volunteers (led by @clifff and @sethadam1) and funded by donations.

Administered by:

Server stats:

279
active users

#COVID

183 posts146 participants6 posts today

Statt bei der "#Covid-Aufarbeitung" immer nur zu monieren, wie viel zu streng die Maßnahmen doch gewesen seien, sollte man sich in meinen Augen viel mehr damit befassen, was wir aus dieser Erfahrung gelernt haben und in die nächste #Pandemie mitnehmen wollen. Denn eins ist sicher, die nächste Pandemie kommt bestimmt. Und wenn wir da nur mit "das machen wir aber nicht mehr" reingehen, machen wir am Schluss einfach weniger als zuvor - und nehmen so mehr Todesopfer und Langzeitfolgen in Kauf.

#LongCOVIDAwarenessDay
Laut Astrid Weber (Koblenzer Post-Covid-Ambulanz) hätten sie immer mehr Betroffene. Es seien vor allem sehr viele Kinder betroffen, die im Herbst 2024 an einer akuten #COVID-Infektion erkrankt gewesen seien. Das sei oft die 3. oder 4. Infektion gewesen.

Mittlerweile steige auch die Zahl der Dauerbetreuung kontinuierlich an. Das Risiko von #LongCOVID werde insgesamt unterschätzt. Long COVID werde uns nicht mehr verlassen.

#ILCAD2025 #COVID19

swr.de/swraktuell/rheinland-pf

SWR AktuellInterview mit Ärztin Astrid Weber: "Long Covid wird uns nicht mehr verlassen"Fünf Jahre nach Beginn der Pandemie hat Covid für die meisten seinen Schrecken verloren. Doch Corona ist nicht für alle vorbei. Bei Ärztin Astrid Weber in der Koblenzer Post-Covid-Ambulanz melden sich immer mehr Betroffene.
Continued thread

Second time #CDC has reported estimates for more than two regions at a time since October.

To be clear, national data used for chart above are modeled on regional data collection.

LP.8.1 now estimated at majority in Great Lakes, nearing majority in NY/NJ and Mid-Atlantic.

XEC (incl. XEC.4) still around a quarter share in all three regions.

[For color key, see: covid.cdc.gov/covid-data-track]

#ThisIsOurPolio #Covid #Covid19 #SARS2 #variants #CovidIsNotOver #CovidIsAirborne #WearAMask #BetterMasks

Continued thread

A FLuQE wavelet opened September, cresting as KP.3.1.1 / MC wave into November. FDA's second-guess vaccine target, KP.2, dropped out in December. Updated #CDC estimates indicate we've been in a JN.1.11 soup pretty much since then.

No new variants broken out by CDC, as KP.1.1.3 / LP descendant LP.8.1 approaches majority.

No recent GISAID data—as Raj's dashboard hasn't updated in near a month.

#ThisIsOurPolio #Covid #Covid19 #SARS2 #variants #CovidIsNotOver #CovidIsAirborne #dataviz #datavis

The mRNA technology behind coronavirus vaccines is now being used to create bespoke vaccines for cancer patients.

"Cancer vaccines weren’t a proper field of research before the pandemic. There was nothing. Apart from one exception, pretty much every clinical trial had failed. With the pandemic, however, we proved that mRNA vaccines were possible.

mRNA cancer vaccines work by giving the body instructions to make a harmless piece of a cancer-related protein. This trains the immune system to recognize and attack cancer cells carrying that protein. Think of it like a training manual for security guards. The vaccine gives the immune system a guide on what cancer looks like, so it knows exactly who to watch for and remove.

Going from mRNA Covid vaccines to mRNA cancer vaccines is straightforward: same fridges, same protocol, same drug, just a different patient.

In the current trials, we do a biopsy of the patient, sequence the tissue, send it to the pharmaceutical company, and they design a personalized vaccine that’s bespoke to that patient’s cancer. That vaccine is not suitable for anyone else. It’s like science fiction.

The UK was ready. We had fridges and we had world-class manufacturing and research facilities. During the pandemic, we had proven we could open and deliver clinical trials fast. Also, the UK had established a genomic global lead with Genomics England and the 100,000 Genome Project. All doctors and nurses in this country are trained in genomics.

So the UK government signed two partnerships: one with BioNTech to provide 10,000 patients with access to personalized cancer treatments by 2030, and a 10-year investment with Moderna in an innovation and technology center with capacity to produce up to 250 million vaccines. The stars were aligned.

For many years, we believed that research is inherently slow. It used to take 20 years to get a drug to market. Most cancer patients, unfortunately, will succumb by the time a drug gets to market. We showed the world that it could be done in a year if you modernize your process, run parts of the process in parallel, and use digital tools.

We have a trial to stop skin cancer coming back after you cut it out. It’s now completed. We over-recruited again, just like every single one of the trials that we ran, and the trial finished one year ahead of schedule. That’s completely unheard of in cancer trials because they normally run over-long.

What will happen now is that, over the next six to 12 months, we will monitor the people in the trial and work out if there’s a difference between the people who took the cancer vaccine and the ones who didn’t. We’re hoping to have results by the end of the year or beginning of 2026. If it’s successful, we will have invented the first approved personalized mRNA vaccine, within only five years of the first licensed mRNA vaccine for Covid. That’s pretty impressive."

- Dr. Lennard Lee, UK National Health Service oncologist and medical director at the Ellison Institute of Technology in Oxford

wired.com/story/wired-health-l

WIRED · Covid Vaccines Have Paved the Way for Cancer VaccinesBy João Medeiros

Bugger. After separate hectic weeks of work and travel, me and my love were looking forward to a weekend together. Sadly, she has just tested positive for Covid. So, after a day of prepping for four days of workshops and coaching next week, I am now having to make contingency plans in case I get it too - and heading home via the pharmacy for more masks and tests.

How about some promising Covid-vaccine-related news? It's all early on, but it's still nice to see — and maybe buried amidst all the other news.

Nasal COVID-19 vaccine based on WashU technology to enter U.S. clinical trials
medicine.washu.edu/news/nasal-

Newly Discovered Antibody Protects Against All COVID-19 Variants
news.utexas.edu/2024/09/03/new

(Of course, who knows what will happen with any vaccine work and/or availability given this administration.)

WashU Medicine · Nasal COVID-19 vaccine based on WashU technology to enter U.S. clinical trials | WashU MedicineTrial will assess safety, efficacy of next-generation vaccine given via nasal spray, inhalation

Five years ago today on Fri. the 13th, I photographed the whiteboards, collected sticky notes, and cleaned out my office for the last time.

Late Sun., told the team to pivot to full remote. Transition was easy, comms good, devs happy, and the project was ultimately a success.

I had barely recovered from a 6-week mystery illness that my office-mate brought back from a trip to NYC. Was on a steroid inhaler, feeling weak & fatigued.

But so hopeful! United, we would flatten the curve!